News

News

An Advocacy Win for Sickle Cell Disease

An Advocacy Win for Sickle Cell Disease As part of a multifaceted initiative to address the burden of sickle cell disease (SCD) in the U.S....

FDA Approves Calaspargase Pegol-mknl for Acute Lymphocytic Leukemia

The FDA approved calaspargase pegol-mknl, an asparagine-specific enzyme, for the treatment of pediatric and young adult patients (ages 1 month to 21 years) with...

Cigna and Express Scripts Seal $54 Billion Merger

Health insurer Cigna completed its $54 billion acquisition of Express Scripts, which manages the prescription plans of more than 80 million Americans. The announcement...

FDA Expands Romiplostim Indication to Pediatric ITP

The U.S. Food and Drug Administration (FDA) approved romiplostim for the treatment of immune thrombocytopenia (ITP) in children younger than age 1 whose disease...

An MRD-Guided Azacitidine Treatment Strategy Delays Hematologic Relapse in MDS and AML

According to results from the phase II RELAZA2 trial, minimal residual disease (MRD)–guided treatment with the hypomethylating agent azacitidine delayed hematologic relapse in patients...

Apixaban AVERTs Cancer-Associated Venous Thromboembolism

In the randomized, placebo-controlled AVERT trial, investigators assessed the safety and efficacy of apixaban thromboprophylaxis in patients with cancer considered to be at intermediate-...
WIB_icon

A Pediatric Regimen Is Effective for Adolescents and Young Adults With ALL

Adolescents and young adults (AYAs) with newly diagnosed acute lymphocytic leukemia (ALL) who received a pediatric-inspired regimen had better survival outcomes than historical controls,...
WIB_icon

Study Identifies Genetic Markers That Predict Radiation-Induced Breast Cancer After Hodgkin Lymphoma

The risk of developing breast cancer is high in women with Hodgkin lymphoma (HL) who have undergone chest radiotherapy (RT), but the role of...

NCI Trims Operating Expenses for 2019

Despite receiving a larger budget for fiscal year 2019 – a $179-million increase over the previous year – the National Cancer Institute (NCI) plans...
WIB_icon

Azacitidine Maintenance Improves Disease-Free Survival in Older Patients with Newly Diagnosed AML

Older patients with acute myeloid leukemia (AML) in complete remission (CR) who received maintenance therapy with subcutaneous azacitidine had longer disease-free survival (DFS), compared...
Advertisement

Current Issue

February 2019, Volume 5, Issue 3

This issue features a look at the unique challenges of developing treatments for orphan diseases, more coverage of the 2018 ASH annual meeting, and more.